Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

566 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPα Interaction as a Potential Cancer Immunotherapy.
Hazama D, Yin Y, Murata Y, Matsuda M, Okamoto T, Tanaka D, Terasaka N, Zhao J, Sakamoto M, Kakuchi Y, Saito Y, Kotani T, Nishimura Y, Nakagawa A, Suga H, Matozaki T. Hazama D, et al. Among authors: tanaka d. Cell Chem Biol. 2020 Sep 17;27(9):1181-1191.e7. doi: 10.1016/j.chembiol.2020.06.008. Epub 2020 Jul 7. Cell Chem Biol. 2020. PMID: 32640189 Free article.
Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy.
Yanagita T, Murata Y, Tanaka D, Motegi SI, Arai E, Daniwijaya EW, Hazama D, Washio K, Saito Y, Kotani T, Ohnishi H, Oldenborg PA, Garcia NV, Miyasaka M, Ishikawa O, Kanai Y, Komori T, Matozaki T. Yanagita T, et al. Among authors: tanaka d. JCI Insight. 2017 Jan 12;2(1):e89140. doi: 10.1172/jci.insight.89140. JCI Insight. 2017. PMID: 28097229 Free PMC article.
Anti-human SIRPα antibody is a new tool for cancer immunotherapy.
Murata Y, Tanaka D, Hazama D, Yanagita T, Saito Y, Kotani T, Oldenborg PA, Matozaki T. Murata Y, et al. Among authors: tanaka d. Cancer Sci. 2018 May;109(5):1300-1308. doi: 10.1111/cas.13548. Epub 2018 Apr 15. Cancer Sci. 2018. PMID: 29473266 Free PMC article.
566 results